Guided Therapeutics (GTHP) Cash from Operations (2016 - 2025)

Guided Therapeutics (GTHP) reported Cash from Operations of 291000.0 for Q4 2025, up 12.35% on a YoY basis from 259013.4 in Q4 2024, and down 5.05% sequentially from 277000.0 in Q3 2025.

Guided Therapeutics (GTHP) Cash from Operations (2016 - 2025) Analysis & Trends

Guided Therapeutics (GTHP) has 10 years of Cash from Operations data on file, last reported at 291000.0 in Q4 2025.

  • For the quarter ending Q4 2025, Cash from Operations rose 12.35% year-over-year to 291000.0; the trailing twelve-month figure through Dec 2025 stood at 1068000.0 (up 4.56% YoY), and the FY2025 full-year result was 1068000.0, up 4.56% from the prior year.
  • Cash from Operations fell to 291000.0 in Q4 2025, from 277000.0 in the prior quarter.
  • In the past five years, Cash from Operations ranged from a high of 159000.0 in Q4 2021 to a low of 739000.0 in Q3 2021.
  • A 5-year average of 350200.0 and a median of 334000.0 in 2023 frame the typical range for Cash from Operations.
  • Across the five-year window, Cash from Operations surged 148.04% in 2021 and tumbled 313.21% in 2022, its largest moves.
  • Tracing GTHP's Cash from Operations over 5 years: stood at 159000.0 in 2021, then tumbled by 313.21% to 339000.0 in 2022, then gained by 0.88% to 336000.0 in 2023, then advanced by 1.19% to 332000.0 in 2024, then climbed by 12.35% to 291000.0 in 2025.
  • Business Quant data shows GTHP's Cash from Operations at 291000.0 in Q4 2025, 277000.0 in Q3 2025, and 169000.0 in Q2 2025.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Cash from Operations (Qtr)
1 Abbott Laboratories 201.40 Bn 194.75 Bn 6.27 Bn 1.32 Bn
2 Stryker 122.29 Bn 119.41 Bn 3.81 Bn 581.00 Mn
3 Medtronic 105.01 Bn 96.40 Bn 6.41 Bn 2.57 Bn
4 Boston Scientific 64.81 Bn 63.59 Bn 3.61 Bn 348.00 Mn
5 Edwards Lifesciences 55.28 Bn 51.60 Bn 1.29 Bn 43.80 Mn
6 Dexcom 29.06 Bn 27.94 Bn 750.30 Mn 525.60 Mn
7 Koninklijke Philips 29.02 Bn 25.93 Bn 2.07 Bn 220.10 Mn
8 GE HealthCare Technologies 28.27 Bn 26.20 Bn 1.98 Bn 290.00 Mn
9 Smith & Nephew 25.80 Bn 25.22 Bn - -
10 Guided Therapeutics 21.96 Mn 21.89 Mn 458,000.00 -291,000.00

Historic Data

Download Data
DateValue
Dec 31, 2025 -291,000.00
Dec 31, 2025 -291,000.00
Sep 30, 2025 -277,000.00
Sep 30, 2025 -277,000.00
Jun 30, 2025 -169,000.00
Jun 30, 2025 -169,000.00
Mar 31, 2025 -331,000.00
Mar 31, 2025 -331,000.00
Dec 31, 2024 -332,000.00
Dec 31, 2024 -332,000.00
Sep 30, 2024 -473,000.00
Sep 30, 2024 -473,000.00
Jun 30, 2024 -214,000.00
Jun 30, 2024 -214,000.00
Mar 31, 2024 -100,000.00
Mar 31, 2024 -100,000.00
Dec 31, 2023 -336,000.00
Dec 31, 2023 -336,000.00
Sep 30, 2023 -473,000.00
Sep 30, 2023 -473,000.00